Melatonin Decreases Eye Pressure in Normotensive Patients

Last updated: August 10, 2018
Sponsor: Kahramanmaras Sutcu Imam University
Overall Status: Completed

Phase

N/A

Condition

Depression

Treatment

N/A

Clinical Study ID

NCT03193112
KahramanmarasSIU
  • Ages 18-66
  • All Genders

Study Summary

Agomelatine is a melatonin drug used to treat depressive disorder. Agomelatine may also some effects on ocular pressures. In this study, we aimed to demonstrate that melatonin decreases intraocular pressures when given depressive patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Depressive patients suitable for Agomelatine therapy for the treatment of theirprimary disease.

Exclusion

Exclusion Criteria:

  • Any past history of ocular surgery, ocular trauma or existing ocular diseases

Study Design

Total Participants: 20
Study Start date:
June 16, 2017
Estimated Completion Date:
June 15, 2018

Study Description

Melatonin has been shown to be effective to decrease intraocular pressure in experimental animal researches. Agomelatine is a melatonin derivative drug approved for the treatment of depression, which is also available in our country. Depending on animal experiments, it can be assumed that agomelatine can decrease intraocular pressure. Demonstrating that agomelatine is effective to reduce eye pressure may give a concurrent treatment of depressive patients with glaucoma. With this it may be possible to treat both diseases at the same time with single drug. In this study, the researchers intended to investigate the changes in ocular tension in normotensive depressive patients treated with agomelatine.

Connect with a study center

  • Kahramanmaras Sutcuimam University Ophthalmology Department

    Kahramanmaraş, 46050
    Turkey

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.